# A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

> **NCT04396574** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 566 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Lasmiditan

## Key facts

- **NCT ID:** NCT04396574
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-30
- **Primary completion:** 2025-12-04
- **Final completion:** 2025-12-04
- **Target enrollment:** 566 (ACTUAL)
- **Why stopped:** Study terminated due to strategic business decision
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04396574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04396574, "A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04396574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*